September 20, 2021
FDA committee votes against COVID-19 vaccine boosters for general population
Editor's Note
The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee on September 17 voted that there was not enough safety and effectiveness data to approve a third Pfizer COVID-19 vaccine dose for those 16 years and older.
The committee did vote to recommend approval of a booster dose for people 65 years and older and those at high risk of severe COVID-19.
The committee also recommended approval of a booster for those with occupational risks, such as healthcare workers and teachers.
Free Daily News
- Market volatility threatens hospitals’ liquidity as tariff-driven costs rise
- Study: CT scan radiation could drive 5% of future cancer cases
- New studies, surgical feats advance organ transplant medicine
- Commentary: Cyberattacks threaten financial survival of surgical practices
- Tariffs strain supply chains, split medical manufacturing community
- Study: Systemic gender bias embedded in surgical practice
- Literature review: Endoscope disinfection failures highlight need for stronger sterilization practices
- Study: GLP-1 drugs heighten risk of gastric residue but not perioperative pulmonary aspiration
- OAS CAHPS compliance soars to 96% among ASCs, vendor satisfaction also improves
- Knee surgical robot market set to surge, projected to reach $5.9B by 2032
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement